31.06USD-0.42%Mkt Cap: 2.57B USDP/E: —Last update: 2026-06-01
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered,…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.57B USD
Enterprise Value1.95B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-154.65M USD
Revenue/Share—
Last Price31.06 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-16.23
PEG—
EV/EBITDA-11.39
EV/Revenue—
P/S—
P/B3.97
EPS (TTM)-1.97
EPS (Forward)-1.94
52W Range
12.5953% of range47.65
52W High47.65 USD
52W Low12.59 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.91%
ROA-23.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.42M USD
CapEx (TTM)15.00K USD
FCF Margin—
FCF Yield-3.05%
Net Debt-646.06M USD
Net Debt/EBITDA3.77
Balance Sheet
Debt/Equity—
Current Ratio44.33
Quick Ratio43.90
Book Value/Sh7.931 USD
Cash/Share7.831 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)48.50 USD
Target Range30.00 USD – 56.00 USD
# Analysts8
Ownership
Shares Out.82.50M
Float60.37M
Insiders0.72%
Institutions116.53%
Short Interest
Short Ratio8.3d
Short % Float13.28%
Short % Out.10.94%
Shares Short9.02M
Short (prev mo.)8.78M
Technical
SMA 5027.54 (+12.8%)
SMA 20032.36 (-4.0%)
Beta0.48
S&P 52W Chg27.94%
Avg Vol (30d)1.03M
Avg Vol (10d)1.32M
Technical Indicators
RSI (14)60.9
MACD0.6921
MACD Signal0.3641
MACD Hist.+0.3280
BB Upper32.13 USD
BB Middle29.06 USD
BB Lower26.00 USD
BB Width21.09%
ATR (14)1.620 USD
Vol Ratio (20d)0.45x